PRESS RELEASE
27 November 2026 09:45:00 CET

AcouSort selected to present at HealthTech Investor Summit

AcouSort has been invited to participate in the pitch program at the HealthTech Investor Summit in Bruges on December 1-2, where CEO Torsten Freltoft will present the company and its acoustofluidic technology to an audience of investors and industry representatives.

The HealthTech Investor Summit brings together companies, investors and stakeholders within the healthtech and life science sectors. AcouSort's participation provides an opportunity to present the company's technology platform and commercial strategy, with a particular focus on the potential of acoustofluidics to enable automated and integrated sample preparation in future diagnostic and life science applications.

"We are very pleased to have been invited to present AcouSort at the HealthTech Investor Summit. It is an excellent opportunity for presenting our technology and commercial strategy to an investor audience and to highlight the role we believe acoustofluidics can play in the continued automation of sample preparation in life science and diagnostics," says Torsten Freltoft, CEO of AcouSort.

FOR FURTHER INFORMATION ABOUT ACOUSORT, PLEASE CONTACT:
Torsten Freltoft, CEO
Telephone: +45 2045 0854
E-mail: **torsten.freltoft@acousort.com**

ABOUT ACOUSORT
AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify, and stain cells, exosomes, and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases, and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Tapper Partners AB.